Get the Stockscreener App
855.35
1.14%
9.63
After Hours:
854.02
-1.33
-0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $855.35, with a volume of 3.02M.
It is up +1.14% in the last 24 hours and up +13.95% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$845.72
Open:
$851.69
24h Volume:
3.02M
Relative Volume:
0.66
Market Cap:
$809.55B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
56.72
EPS:
15.0808
Net Cash Flow:
$-50.20M
1W Performance:
+4.33%
1M Performance:
+13.95%
6M Performance:
+13.49%
1Y Performance:
-7.00%
1-Day Range:
$845.70
$860.25
1-Week Range:
$816.10
$860.25
52-Week Range:
$623.78
$937.00
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
855.35 | 758.15B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.08 | 456.84B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
230.69 | 408.50B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.06 | 256.13B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.50 | 215.81B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is. - MSN
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions - FinancialContent
Lobbying Update: $10,000 of ELI LILLY & COMPANY lobbying was just disclosed - Quiver Quantitative
Eli Lilly’s New Study on Orforglipron: A Potential Game-Changer for Stress Urinary Incontinence - TipRanks
US-based Eli Lilly to invest $1 billion in India - The Indian EYE
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? - Yahoo Finance
Eli Lilly and Company ($LLY) Stock: Appoints Former FDA Biologics Head Peter Marks as Senior VP of Molecule Discovery - CoinCentral
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market - The Motley Fool
Tencent- and Meituan-Backed Chinese Obesity Drug Maker Sciwind Eyes Hong Kong IPO - Benzinga
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $925 From $825, Maintains Overweight Rating - MarketScreener
Notis McConarty Edward Acquires 1,424 Shares of Eli Lilly and Company $LLY - MarketBeat
Capital Management Associates Inc Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Dempze Nancy E Increases Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Richmond United to vacate West Creek soccer complex, make way for $5B Eli Lilly pharma facility - Richmond BizSense
Eli Lilly To Invest $1 Billion In India, Boosts Hyderabad’s Pharma Sector - indica News
US pharma company: Eli Lilly to invest USD 1 billion in India; Piyush Goyal reacts - ET Now
Major Shareholder Cashes In on Eli Lilly & Co Stock! - TipRanks
Eli Lilly’s SWOT analysis: stock poised for growth amid obesity market boom - Investing.com
Judge Drops Eli Lilly’s Suit Over Compounded Zepbound, Mounjaro - Bloomberg Law News
Lilly Endowment sells $22.7 million in Eli Lilly shares - Investing.com
Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery - MarketScreener
Lilly outlines $1bn India manufacturing expansion - European Pharmaceutical Review
Guggenheim Maintains Eli Lilly and (LLY) Buy Recommendation - Nasdaq
Eli Lilly Stays On Track With Wall Street Projections - Finimize
Is Eli Lilly’s Recent $1B India Investment a Game Changer for Its Valuation in 2025? - Yahoo Finance
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875 - Yahoo Finance
Eli Lilly (LLY) Receives Updated 'Buy' Rating and Raised Price T - GuruFocus
Guggenheim raises Eli Lilly stock price target to $948 on tirzepatide strength - Investing.com
Eli Lilly: Beyond Weight Loss - AOL.com
Puzo Michael J Has $3.57 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Kidder Stephen W Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Peter Marks finds a new home at Eli Lilly - FirstWord Pharma
Somerville Kurt F Has $5.65 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly to Build $5B Manufacturing Facility in Virginia - The Healthcare Technology Report.
Eli Lilly Stock Eases After-Hours: Ex-FDA Official Ejected By RFK Jr. Joins Firm — Will Investors Warm Up? - MSN
Major Shareholder Makes a Massive Move with Eli Lilly & Co Stock! - TipRanks
Analysis: Cork operations of Eli Lilly underpin Ozempic maker Novo Nordisk's dwindling market dominance - Irish Examiner
Eli Lilly taps former US FDA official Peter Marks to head infectious disease - Yahoo
Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly - statnews.com
Former FDA CBER Head Peter Marks Joins Eli Lilly Six Months After Departure - geneonline.com
Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly - Barron's
Former FDA vaccine regulator takes job at Eli Lilly - Washington Examiner
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator - BioSpace
Peter Marks, former top FDA vaccine official, joins Eli Lilly - BioPharma Dive
Lilly Endowment sells $137 million in Eli Lilly shares - Investing.com
Eli Lilly (LLY) Stock Rises Amid New Executive Appointment - GuruFocus
Former FDA vaccine regulator Peter Marks joins Eli Lilly - StreetInsider
Eli Lilly says Peter Marks named senior VP of molecule discovery & head, infectious disease - MarketScreener
After high-profile FDA exit, Peter Marks lands at Eli Lilly - Fierce Biotech
Former FDA Official Joins Eli Lilly (LLY) for Research Leadershi - GuruFocus
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):